Rona Therapeutics is a Shanghai-based clinical-stage platform company specializing in nucleic acid drug research and development, led by CEO and Founder Ms. Stella SHI. The company advances siRNA programs generated from a next-generation siRNA platform, focused on metabolic diseases and CNS degenerative disorders. Its lead program, RN0191—a PCSK9 siRNA—completed Phase 1 studies in Australia and China and is ready for Phase 2 development for hypercholesterolemia. RN0361 is expected to enter the clinic in 2024 Q2 for hypertriglyceridemia, and several additional programs are at IND-enabling stages for kidney disease, obesity, and cardiometabolic diseases. Rona is also working to expand its extra-hepatic delivery platform into the CNS and other tissues. The company completed a $35M Series A+ financing to fund global development of its metabolic siRNA pipeline and platform expansion. Rona Therapeutics operates an integrated platform dedicated to discovery, development and manufacturing of RNA therapeutics, with an emphasis on a proprietary delivery platform. Its RNA medicines are described as modular and programmable, designed to target metabolic, neurological and ophthalmology diseases via different delivery systems. The company intends to advance its proprietary delivery platform and its initial pipeline of therapeutics using the proceeds from the recent financing. Rona is building facilities to expand nucleic acid synthesis, oligonucleotide chemical modification, delivery capabilities, RNA biology and manufacturing capacity. Founded in 2021, the company is led by CEO and co-founder Stella SHI. The focus is on creating RNA medicines with more specific, stable and prolonged effects.

Total raised

$68M

Funding rounds

2

Latest round

Series A

Latest activity

Jul 2024